Daily Stock Analysis, ATRC, AtriCure Inc, priceseries

AtriCure Inc. Daily Stock Analysis
Stock Information
Open
17.39
Close
16.96
High
17.53
Low
16.83
Previous Close
17.22
Daily Price Gain
-0.26
YTD High
18.95
YTD High Date
Jan 3, 2018
YTD Low
14.88
YTD Low Date
Feb 9, 2018
YTD Price Change
-1.51
YTD Gain
-8.18%
52 Week High
25.18
52 Week High Date
Jul 31, 2017
52 Week Low
14.88
52 Week Low Date
Feb 9, 2018
52 Week Price Change
-0.43
52 Week Gain
-2.44%
Company Information
Stock Symbol
ATRC
Exchange
NasdaqGM
Company URL
http://www.atricure.com
Company Phone
513-755-4100
CEO
Michael H. Carrel
Headquarters
Ohio
Business Address
7555 INNOVATION WAY, MASON, OH 45040
Sector
separate tissues to provide access to key anatomical structures that are targeted for ablation; and Estech cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Industry Category
Health Services
Industry Group
Medical Instruments & Supplies
CIK
0001323885
About

AtriCure, Inc. engages in the provision of innovative products, professional education, and support for the treatment of atrial fibrillation. Its product, Isolator Synergy Ablation System, is a surgical device that treats the persistent longstanding persistent forms of atrial fibrillation in patients undergoing certain open concomitant procedures. Its cryoICE cryosurgery product offers a variety of cryoablation devices for use in multiple different types of cardiothoracic surgery. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.

Description

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias and to provide temporary pain relief to thoracic surgery patients via ablation of peripheral nerves; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; and Estech cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.